Chronic viral hepatitis B in the first and second trimesters
Conditions
Interventions
Tenofovir:None
Tenofovir alafenol:None
Sponsors
The Third Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1.female; 2.Between 20-40 years old; 3.HBsAg positive = 6 months; 4.ALT > 40 U/L at 0 to 24 weeks of pregnancy and antiviral therapy with TAF/TDF; 5.Voluntarily accept regular use of TAF/TDF 1 time per day until the end of labor or long-term use; 6.Good adherence;
Exclusion criteria
Exclusion criteria: 1.Concomitant viral hepatitis A, C, E or other hepatotropic virus infection or AIDS; 2.Concomitant cirrhosis, liver cancer, or other chronic liver disease; 3.Patients with diseases of important organs such as heart, lungs, and kidneys; 4.Accompanied by autoimmune hepatitis, autoimmune diseases, hypertension, diabetes, thyroid disease; 5.Those who have complications in previous pregnancies; 6.Those who have had fetal or neonatal growth and development defects in previous pregnancies; 7.Previous or ongoing use of nephrotoxic medications, glucocorticoids, nonsteroidal anti-inflammatory drugs, cytotoxic drugs, or immunomodulators; 8.History of anti-hepatitis B virus use within 1 year before pregnancy; 9.Premedication ultrasound showed fetal malformations, fetal development abnormalities, placental abnormalities, and threatened abortion;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ALT; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hepatitis B in half /HbsAg;HBV-DNA;Deformity rate;Pregnancy complications;Growth and development data;Mode of delivery;Liver imaging changes; | — |
Countries
China
Contacts
Public ContactXingfei Pan
The Third Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed